{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T18:25:53Z","timestamp":1750098353697,"version":"3.40.3"},"reference-count":50,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Classical Hodgkin lymphoma (cHL) is associated with excellent outcomes with standard frontline chemotherapy or combined modality therapy. However, up to 25% of patients will have relapsed or primary refractory (RR) cHL. Improving the cure rate with frontline treatment, treatment-related complications and late effects, and poor therapy tolerance with high relapse rates in older patients are unmet needs in the initial management of cHL. The introduction of novel therapies, including the CD30-directed antibody drug conjugate brentuximab vedotin and PD-1 blockade (ie, pembrolizumab or nivolumab), has transformed the treatment of RR cHL and has the potential to address these unmet needs in the frontline setting. Incorporation of these potent, targeted immunotherapies into frontline therapy may improve outcomes, may allow for de-escalation of therapy without sacrificing efficacy to reduce treatment complications, and may allow for well-tolerated and targeted escalation of therapy for patients demonstrating an insufficient response. In this article, we provide a case-based approach to the use of novel agents in the frontline treatment of cHL.<\/jats:p>","DOI":"10.1182\/hematology.2022000363","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:15:35Z","timestamp":1670602535000},"page":"706-716","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Incorporating novel agents into frontline treatment of Hodgkin lymphoma"],"prefix":"10.1182","volume":"2022","author":[{"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"first","affiliation":[{"name":"Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"17","key":"2025040718014152500_hem2022000363C1","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"2025040718014152500_hem2022000363C2","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025040718014152500_hem2022000363C3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2018-01-827246","article-title":"CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET","volume":"132","author":"Straus","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2025040718014152500_hem2022000363C4","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 Trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025040718014152500_hem2022000363C5","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","article-title":"ABVD (8 cycles) versus BEACOPP (4 escalated cycles \u22654 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial","volume":"25","author":"Mounier","year":"2014","journal-title":"Ann Oncol"},{"issue":"17","key":"2025040718014152500_hem2022000363C6","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score \u22653, high-risk hodgkin lymphoma: first results of the phase III EORTC 20012 Intergroup Trial","volume":"34","author":"Carde","year":"2016","journal-title":"J Clin Oncol"},{"issue":"18","key":"2025040718014152500_hem2022000363C7","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025040718014152500_hem2022000363C8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1200\/OP.20.01020","article-title":"PD-1 blockade in classic Hodgkin lymphoma","volume":"17","author":"Ansell","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"14","key":"2025040718014152500_hem2022000363C9","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025040718014152500_hem2022000363C10","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"2025040718014152500_hem2022000363C11","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"2025040718014152500_hem2022000363C12","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2025040718014152500_hem2022000363C13","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"27","key":"2025040718014152500_hem2022000363C14","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose- reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2025040718014152500_hem2022000363C15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025040718014152500_hem2022000363C16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/bloodadvances.2019001023","article-title":"Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I\/IIA Hodgkin lymphoma","volume":"4","author":"Illidge","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2025040718014152500_hem2022000363C17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2025040718014152500_hem2022000363C18","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/blood.2019001272","article-title":"Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"issue":"20","key":"2025040718014152500_hem2022000363C19","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025040718014152500_hem2022000363C20","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/bloodadvances.2020001871","article-title":"ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma","volume":"4","author":"Park","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2025040718014152500_hem2022000363C21","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL Trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10","key":"2025040718014152500_hem2022000363C22","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2025040718014152500_hem2022000363C23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2021-144610","article-title":"Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma","volume":"138","author":"Lynch","year":"2021","journal-title":"Blood"},{"issue":"25","key":"2025040718014152500_hem2022000363C24","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"2025040718014152500_hem2022000363C25","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2025040718014152500_hem2022000363C26","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"issue":"10114","key":"2025040718014152500_hem2022000363C27","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"2025040718014152500_hem2022000363C28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"2025040718014152500_hem2022000363C29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"2025040718014152500_hem2022000363C30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2025040718014152500_hem2022000363C31","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"issue":"12","key":"2025040718014152500_hem2022000363C32","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1080\/10428194.2020.1791846","article-title":"Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III\/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy","volume":"61","author":"Straus","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"16, suppl","key":"2025040718014152500_hem2022000363C33","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2022.40.16_suppl.7503","article-title":"First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III\/IV classical Hodgkin lymphoma: an updated analysis of ECHELON-1","volume":"40","author":"Ansell","year":"2022","journal-title":"J Clin Oncol"},{"issue":"23","key":"2025040718014152500_hem2022000363C34","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025040718014152500_hem2022000363C35","first-page":"23","article-title":"SWOG S1826: a phase III, randomized study of nivolumab plus AVD or brentuximab vedotin plus AVD in patients with newly diagnosed advanced STage classical Hodgkin Lymphoma","volume":"136","author":"Herrera","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2025040718014152500_hem2022000363C36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"2025040718014152500_hem2022000363C37","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2025040718014152500_hem2022000363C38","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"issue":"26","key":"2025040718014152500_hem2022000363C39","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Forero-Torres","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2025040718014152500_hem2022000363C40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.17073","article-title":"Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)","volume":"193","author":"Gibb","year":"2021","journal-title":"Br J Haematol"},{"issue":"26","key":"2025040718014152500_hem2022000363C41","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged \u226560 years with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"issue":"15, suppl","key":"2025040718014152500_hem2022000363C42","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.1200\/JCO.2020.38.15_suppl.8029","article-title":"Brentuximab vedotin and bendamustine as first-line treatment of Hodgkin lymphoma in the elderly (HALO Trial)","volume":"38","author":"de Colella","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025040718014152500_hem2022000363C43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-136583","article-title":"Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients","volume":"136","author":"Yasenchak","year":"2020","journal-title":"Blood"},{"issue":"15, suppl","key":"2025040718014152500_hem2022000363C44","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1200\/JCO.2018.36.15_suppl.7542","article-title":"Long-term follow-up of brentuximab vedotin\u200a\u00b1\u200adacarbazine as first line therapy in elderly patients with Hodgkin lymphoma","volume":"36","author":"Friedberg","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025040718014152500_hem2022000363C45","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/bjh.16499","article-title":"Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma","volume":"189","author":"LaCasce","year":"2020","journal-title":"Br J Haematol"},{"issue":"11","key":"2025040718014152500_hem2022000363C46","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"},{"issue":"30","key":"2025040718014152500_hem2022000363C47","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15, suppl","key":"2025040718014152500_hem2022000363C48","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2021.39.15_suppl.7507","article-title":"CALGB 50801 (Alliance): PET adapted therapy in bulky stage I\/II classic Hodgkin lymphoma (cHL)","volume":"39","author":"LaCasce","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025040718014152500_hem2022000363C49","first-page":"630","article-title":"Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial","volume":"20","author":"Horning","year":"2002","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025040718014152500_hem2022000363C50","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2021-147891","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced stage classic Hodgkin lymphoma: preliminary safety results from the single-arm phase 2 study (SGN35-027 Part B)","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/706\/2021713\/706kambhampati.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/706\/2021713\/706kambhampati.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T20:11:39Z","timestamp":1744056699000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/706\/493479\/Incorporating-novel-agents-into-frontline"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000363","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"type":"print","value":"1520-4391"},{"type":"electronic","value":"1520-4383"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}